Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN

Delayed Quote. Delayed  - 05/27 09:59:58 pm
89.09 USD   +2.10%
05/25DJSAREPTA : FDA's Decision on Dystrophy Drug Delayed
05/16 ABSCI : Appoints Daniel Gold, Ph.D. to Board of Directors
05/05 NASDAQ 100 MOVE : Bmrn, disca
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2016 05/24/2016 05/25/2016 05/26/2016 05/27/2016 Date
85.51(c) 87.95(c) 88.81(c) 87.26(c) 89.09(c) Last
831 160 911 797 1 062 649 877 619 836 584 Volume
-1.09% +2.85% +0.98% -1.75% +2.10% Change
More quotes
Financials ($)
Sales 2016 1 091 M
EBIT 2016 -336 M
Net income 2016 -363 M
Debt 2016 352 M
Yield 2016 -
Sales 2017 1 332 M
EBIT 2017 -196 M
Net income 2017 -238 M
Debt 2017 300 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 13,6x
EV / Sales 2017 11,1x
Capitalization 14 461 M
More Financials
Company
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of innovative pharmaceuticals for serious diseases and medical conditions.It operates its business through one segment, the biopharmaceutical development and commercialization segment.Its company's products include... 
Sector
Pharmaceuticals
Calendar
06/06Shareholder meeting
More about the company
Surperformance© ratings of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL IN
05/25DJSAREPTA : FDA's Decision on Dystrophy Drug Delayed
05/16 ABSCI : Appoints Daniel Gold, Ph.D. to Board of Directors
05/05 NASDAQ 100 MOVERS : Bmrn, disca
05/04 BIOMARIN PHARMACEUTICAL : Announces EMA Grants Accelerated Assessment for Cerlip..
05/04 BioMarin to Attend Upcoming Investor Conferences
05/03 BIOMARIN PHARMACEUTICAL : Announces EMA Grants Accelerated Assessment for Cerlip..
05/03 BioMarin Announces EMA Grants Accelerated Assessment for Cerliponase Alfa, E..
04/28 BIOMARIN PHARMACEUTICAL : reports 1Q loss
04/28 BIOMARIN PHARMACEUTICAL INC : Results of Operations and Financial Condition, Fin..
04/28 BioMarin Announces First Quarter 2016 Financial Results
More news
Sector news : Generic Pharmaceuticals
09:12a NOVO NORDISK A/S : Semaglutide demonstrated superior glycaemic control vs insuli..
09:07a Samsung Bioepis receives final European approval for its Remicade copy
08:06a BIOGEN : FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, A..
07:07a ROCHE : First PT/INR home self-testing device with Bluetooth technology enabling..
06:05a BIOGEN : AZN's Falcon Hits Goal, FDA Approves MS Drug, CANF Awaits Data In June
More sector news : Generic Pharmaceuticals
News from SeekingAlpha
05/26 FDA OKs Behring's single-chain AFSTYLA for hemophilia A
05/25 Best Performing Nasdaq 100 Stocks
05/23 2 End Of May FDA Decisions To Watch
05/22 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2016 Update
04/28 BioMarin Pharmaceutical (BMRN) Jean-Jacques Bienaimé on Q1 2016 Results - Ear..
Advertisement
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Technical analysis trends BIOMARIN PHARMACE...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions